Search This Blog

Wednesday, April 30, 2025

Immunic (IMUX) Shares Fall on Phase 2 Trial Results for Multiple Sclerosis Drug

 

  • Immunic (IMUX, Financial) shares fell significantly in premarket trading following Phase 2 trial results.
  • The trial demonstrated a 20% reduction in disability worsening for multiple sclerosis but only a modest brain volume improvement.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)